Navigation Links
Resisting the flu

McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre (RI-MUHC). "The results from our study now suggest that one effective way of countering influenza infections may instead be offered by enhancing the body's resistance to the virus."

Like many other battles, fighting the flu is a combination of both control and defence. On the one hand, on the control end of the process, our immune system comes into play to prevent the virus from replicating inside our cells, and attacking with increasing strength. At the same time, on the defensive side, our bodies need to actively resist the destruction and harmful cell death that is caused by the virus.

By investigating the role played by cIAP2 in mice with the H1N1 influenza A virus, what Saleh and her team discovered was that the enzyme is necessary to control the nature of cell death during influenza infection. They found that cIAP2, which functions by modifying and activating survival factors in the cell, steers the body away from an inflammatory and auto-destructive process known as necrotic death. The enzyme is, in effect, a gatekeeper of cell death.

In its absence, the same factors that depend on cIAP2 to keep the cell alive, reveal a destructive side and induce a harmful form of cell death. cIAP2 therefore not only protects the infected cells from dying in such a manner, but also protects uninfected neighbouring cells in the same tissue. By doing so, this enzyme increases the resistance of the lung to influenza infection and associated pathology.

The researchers believe that the identification of this pathway of resistance to flu opens a number of avenues for future drug development. Ian Rodrigue-Gervais is a post-doctoral fellow in Prof. Saleh's lab and one of the authors on the paper. According to him, what is truly exciting about this discovery is that it suggests that it may be possible to suppress features of flu-inflicted tissue injury. "What we saw in this study is that if the enzyme cIAP2 is present, the host can better tolerate the infection and then reduce the illness."

Contact: Katherine Gombay
McGill University

Post Your Comments:
Related Image:
Resisting the flu
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: